Eagle Pharmaceuticals (EGRX) Downgraded by Zacks Investment Research

Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, January 9th.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

EGRX has been the topic of a number of other research reports. Mizuho reissued a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Piper Jaffray Companies restated a “buy” rating and set a $75.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $62.33.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) traded down $1.43 on Tuesday, reaching $58.50. 285,900 shares of the company’s stock were exchanged, compared to its average volume of 220,545. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. Eagle Pharmaceuticals has a 1 year low of $45.05 and a 1 year high of $97.15. The company has a market capitalization of $872.92, a price-to-earnings ratio of 9.42 and a beta of 1.24.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a net margin of 36.95% and a return on equity of 62.60%. research analysts forecast that Eagle Pharmaceuticals will post 2.23 EPS for the current year.

Several institutional investors have recently made changes to their positions in EGRX. Municipal Employees Retirement System of Michigan boosted its position in shares of Eagle Pharmaceuticals by 68.1% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,300 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Eagle Pharmaceuticals by 58.7% in the second quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 908 shares during the period. Schroder Investment Management Group bought a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at about $219,000. Foundry Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at about $224,000. Finally, Kopp Investment Advisors LLC boosted its position in shares of Eagle Pharmaceuticals by 0.3% in the second quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 10 shares during the period.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals (EGRX) Downgraded by Zacks Investment Research” was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.truebluetribune.com/2018/01/18/eagle-pharmaceuticals-egrx-stock-rating-lowered-by-zacks-investment-research.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply